Pharmaceutical

Lobe Sciences Ltd. today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright BIOCONNECT Conference taking place January 10-14, 2022.The presentation will be available on demand through the H.C. Wainwright conference portal, beginning at 7:00 a.m. ET on Monday, January 10, 2022. Registration for the event is accessible via Company will also participate in one-on-one meetings during the ...

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") today announced that Philip Young, CEO and Director, will present at the H.C. Wainwright BIOCONNECT Conference taking place January 10-14, 2022.

The presentation will be available on demand through the H.C. Wainwright conference portal, beginning at 7:00 a.m. ET on Monday, January 10, 2022.

Registration for the event is accessible via https://hcwevents.com/bioconnect/.

The Company will also participate in one-on-one meetings during the conference.

* * *

About Lobe Sciences Ltd.

Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

For further information please contact:

Lobe Sciences Ltd.
Philip J Young, CEO
info@lobesciences.com
Tel: (949) 505-5623

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Disclaimer for Forward-Looking Statements

This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, research and development using psychedelic compounds, and the development of innovative devices and delivery mechanisms to improve mental health and wellness, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment;, that the Company's drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that the Company may not be able to attain the Company's corporate goals and objectives; and other risk factors detailed in the Company's continuous disclosure filings from time to time, as available under the Company's profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109344

News Provided by Newsfile via QuoteMedia

LOBE:CNX
Lobe Sciences

Lobe Sciences

Overview

Lobe Sciences Ltd. (CSE:LOBE,OTCQB: LOBEF) is a life sciences company focused on the research and development of psychedelic medicines. The Company focuses on clinical development of devices and medicines to treat neurological disorders and brain trauma. The Company’s mission is to identify and develop transformative new methods, medicines and devices to improve brain health and provide new pathways for treating brain injuries and neurological disorders. The Company undertakes the development of innovative medicines and devices to treat mental health disorders and improve well-being while building a growing a portfolio of intellectual property to protect our technologies. The Company is working to develop psychedelic compounds as therapeutics.

Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. NAC is a dietary supplement derived from the amino acid L-cysteine. Taking NAC increases the level of glutathione, a potent antioxidant and anti-inflammatory molecule, in cells. Glutathione’s function is to protect cellular compounds such as DNA and prevent damage to them from reactive oxygen species and inflammatory cytokines. It is also used as an antidote for acetaminophen overdose.

Keep reading... Show less
Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD

Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD

"Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder"

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce its patent-pending therapeutic regimen that has been designed for treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder, and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder has been published by the World Intellectual Property Organization.

Keep reading... Show less
Lobe Sciences Announces That Its Shares Will Trade on the OTCQB Market in the United States

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB Market in the United States

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") is pleased to announce that it has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB®. Lobe Sciences' common stock will commence trading on the OTCQB under the symbol "LOBEF" at the opening of the market on December 13, 2021.

Philip Young, CEO & Director, commented, "The admission of our shares on a higher tier of the OTC Marketplace, the OTCQB, is an important step in our development as a publicly traded psychedelic company. The listing is a great achievement for Lobe Sciences as we look to increase investor awareness, broaden our investor base, and continue providing transparency to those seeking investment in our emerging industry."

Keep reading... Show less
Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness

Lobe Sciences Sponsors the International Summit on Psychedelic Therapies for Mental Illness

The largest and most important Psychedelic Medicine Conference in the Southern Hemisphere

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) ("Lobe" or the "Company") today announced that it is a Major Supporter of the upcoming International Summit on Psychedelic Therapies for Mental Illness taking place November 17-20, 2021.

Keep reading... Show less
Lobe Sciences Announces Common Stock to Trade Under the Symbol "LOBEF" in US Markets

Lobe Sciences Announces Common Stock to Trade Under the Symbol "LOBEF" in US Markets

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: LOBEF) ("Lobe" or the "Company") today announced that its common stock ticker will change from "GTSIF" to "LOBEF" and will commence trading under the symbol "LOBEF" in US markets at the opening of the market on November 15, 2021 and will continue to trade under the ticker symbol "LOBE" on the CSE.

Philip Young, CEO, commented, "The ticker change now reflects the name of the company along with our commitment to investigating and developing treatments using alternative and nontraditional medicines to better brain health."

Keep reading... Show less

Lobe Announces Krysalis VX Innovations Inc., a Company Equally Owned by Lobe Sciences Ltd. and Virtual Psychedelics Incorporated, Appointment of Interdisciplinary Team of Advisors

Six Thought Leaders Across Arts, Technology, Academic and Industry Sectors to Advise on the Krysalistm Pod Immersive Treatment Experience

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") today announced that Krysalis VX Innovations Inc. ("Krysalis"), the Virtual experience ("VX")-focused company designing the delivery of immersive, headset-free experiences through the KrysalisTM Pod system that will offer treatment options for cognitive, psychological, motor and functional impairments across various clinical health conditions, has appointed a distinguished and future-facing advisory team composed of Alex McDowell, Jon 9, Austin Blaisdell, and the three minds behind sonic engineering company, Resonant Devices, Kent Noonan, Erik Larson and Casey Atteberry.

Keep reading... Show less
Tinley's Long Beach Facility to Produce 'Green Monké' Sodas on Can Line; Tinley's Closes First Tranche of Non-Brokered Private Placement

Tinley's Long Beach Facility to Produce 'Green Monké' Sodas on Can Line; Tinley's Closes First Tranche of Non-Brokered Private Placement

The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) ("Tinley's" or the "Company") is pleased to announce that international cannabis beverage brand ‘Green Monké' is scheduled to begin can line production of five planned flavours at Tinley's Long Beach Facility in Q1 2022, with production of full-batches expected to repeat near-monthly.

‘Green Monké' Happy Sodas are cannabis-infused sparkling drinks in tropical flavours, formulated with a fast-release microencapsulation emulsion, and only 25 calories per can. ‘Green Monké' THC-infused beverages are currently available in the State of California, and Green Monké THC-infused beverages launched in Canada in October 2021. ‘Green Monké' is owned by St. Peter's Spirits. The Tinley Beverage Company Inc. (CSE:TNY; OTC:TNYBF) ("Tinley's" or the "Company") is pleased to announce that international cannabis beverage brand ‘Green Monké' is scheduled to begin can line production of five planned flavours at Tinley's Long Beach Facility in Q1 2022, with production of full-batches expected to repeat near-monthly.

Keep reading... Show less

CURALEAF COMPLETES ACQUISITION OF BLOOM DISPENSARIES

- Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced the completion of its previously announced acquisition of Bloom Dispensaries ("Bloom"), a vertically integrated, single state cannabis operator in Arizona (the "Transaction"). With the close of the Transaction, Curaleaf's retail footprint has reached 13 dispensaries in Arizona and 121 nationwide.

Boris Jordan , Executive Chairman of Curaleaf, stated, "Bloom is an excellent strategic fit for Curaleaf as it further expands our capacity and retail footprint in Arizona with an attractive set of assets, enabling us to better serve the state's US$1.4 billion -plus annual market opportunity. Adding to these benefits, Bloom will be immediately accretive to our adjusted EBITDA margins. On behalf of the Board of Directors and management team, I am pleased to officially welcome Bloom to the Curaleaf family."

Keep reading... Show less

Curaleaf Opens Two New Florida Dispensaries in Tampa Bay and Largo

Company now has 44 dispensaries in Florida and 119 nationwide

Curaleaf Holdings, Inc. (CSE: CURA OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced plans to open two new dispensaries in Florida by the end of this month. The expansion will increase the Company's retail footprint to 44 dispensaries statewide and 119 across the country.

Keep reading... Show less
Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

Numinus Announces Key Milestones in MAPS-Sponsored MDMA-Assisted Therapy for PTSD Clinical Trial

Numinus has received approvals from Health Canada and the Institutional Ethics Review Board

Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI), a leader in psychedelics-focused mental healthcare, is pleased to announce that it has completed key steps to prepare to enroll participants at its clinics participating in "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX)", sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS).

Keep reading... Show less

Cresco Labs Announces Termination of Blair Wellness Acquisition

Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco Labs" or "the Company"), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the termination of the previously announced definitive agreement to acquire 100% of the outstanding equity interest in Blair Wellness, LLC ("Blair Wellness"), a Baltimore Maryland medical cannabis dispensary (the "Transaction").

"We have terminated the purchase agreement with Blair Wellness due to the failure of certain closing conditions to be met prior to our specified termination date," said Charlie Bachtell, Cresco Labs' CEO & Co-founder. "We will continue to look for other avenues to expand our footprint in Maryland, and execute our strategy of going deep in meaningful, material states."

Keep reading... Show less

Martha Stewart CBD Launches its First-Ever Category Expansion with New Line of CBD Wellness Topicals

New Super Strength CBD Cream, Sleep Science CBD Cream and Daily De-Stress CBD Cream Add to Martha's Wellness Portfolio

 Today, Martha Stewart CBD unveiled Martha Stewart CBD Wellness Topicals, marking the brand's first-ever category expansion in its growing CBD portfolio. Martha Stewart CBD provides consumers with an easy way to manage their needs throughout the day with convenient and trusted CBD products including gummies, oils, softgels and the new CBD Wellness Topicals. Martha Stewart CBD Wellness Topicals offer simple solutions that are easy to use, easy to love, and are a part of Martha's wellness portfolio.

Keep reading... Show less

Latest Press Releases

Related News

×